Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome

Tanriverdi F., Unluhizarci K., Kula M., Guven M., Bayram F., Kelestimur F.

GROWTH HORMONE & IGF RESEARCH, vol.15, no.3, pp.231-237, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 3
  • Publication Date: 2005
  • Doi Number: 10.1016/j.ghir.2005.03.005
  • Journal Name: GROWTH HORMONE & IGF RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.231-237
  • Keywords: Sheehan's syndrome, GH deficiency, GH replacement therapy, IGF-I, bone mineral density, lipid profile, body composition, CARDIOVASCULAR RISK-FACTORS, BONE-MINERAL DENSITY, DEFICIENT ADULTS, HYPOPITUITARY ADULTS, BODY-COMPOSITION, LIPID-METABOLISM, CARBOHYDRATE, METAANALYSIS, CHOLESTEROL, MORTALITY
  • Erciyes University Affiliated: Yes

Abstract

Objective: Growth hormone deficiency (GHD) in adults is associated with abnormal body composition, altered lipid profile, reduced quality of life and osteoporosis. Replacement with recombinant GH results in significant improvements in most of these altered parameters. The most common cause of adult GHD in previous studies was due to pituitary tumors or their treatment. Sheehan's syndrome classically refers to postpartum hypopituitarism due to pituitary necrosis occurring secondary to massive bleeding at or just after delivery. While severe GHD is a well-established feature of Sheehan's syndrome, the effects of Growth hormone replacement therapy (GHRT) in these patients has not been extensively investigated. The present study was therefore designed to investigate the effects of GHD and GHRT in patients with Sheehan's syndrome.